Tag: CMS

Value-based contracts — big talk, big deal, or real deal?

Pharmaceutical companies guaranteeing results and paying for failures? Payers paying more if a cancer patient has a shorter lifespan on a specific drug? Pharma guaranteeing the control of cholesterol? A few years ago, these seemed as unlikely as a biosimilar version of a blockbuster biologic. Now value-based contracting (VBC) seems to be the hottest topic in payer-pharmaceutical company relationships.l?

Read more
Biosimilars Are Coming, Biosimilars Are Coming!

Biosimilars are knocking at our doors, and they certainly have a lot to say. Biosimilar products are biological products that are approved based on showing that they are highly similar to FDA-approved biological products, known as reference products, showing no clinically meaningful differences in terms of safety and effectiveness.

Read more